| abstract |
The present invention relates to 4- (4-pyridyl) -benzamides of the formula (I). Compounds I have valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to the modulation of Rho-kinases (ROCKs). R1 and R2 are, independently of one another, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1-C8-halokyl, C1-C8-alkoxy or C1-C8-haloalkoxy; R3, R4, R5 and R6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, amino, C1-C8 -alkylamino or di- (C1-C8-alkyl) -amino; R7 is hydrogen, C1-C8-alkyl, C1-C8-haloalkyl, aryl or aryl-C1-C8-alkyl; R8 is a group of the formula -XW, wherein X is an individual bond, C1-C4-alkylene or C1-C4-alkylene, where the alkylene group in the three radicals finally mentioned may be linear or branched and may be partial or totally halogenated and / or it can be substituted by a hydroxyl group and / or it can be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a heterocyclic ring, saturated, partially saturated or aromatic with 5 or 6 members, which contains as ring members, 1, 2, or 3 heterogeneous atoms selected from O, S and N, and optionally 1 or 2 carbonyl groups; R9 is a group of the formula -YZ, where Z is hydrogen, halogen, OR11, NR12R13, S (O) m-R14, phenyl, which can carry 1, 2, 3, or 4 R15 substituents or a heterocyclic ring saturated, partially saturated or aromatic of 5 or 6 members; and Y is linear or branched C1-C4-alkylene, which may be partially or totally halogenated and / or may be substituted by a hydroxyl group and / or a phenyl ring; or, in the case where Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y may also be an individual bond. |